Click Nucleic Acid Mediated Loading of Prodrug Activating Enzymes in PEG-PLGA Nanoparticles for Combination Chemotherapy

Article abstract of DOI:10.1021/acs.biomac.9b00040

The simultaneous delivery of multiple therapeutics to a single site has shown promise for cancer targeting and treatment. However, because of the inherent differences in charge and size between drugs and biomolecules, new approaches are required for colocalization of unlike components in one delivery vehicle. In this work, we demonstrate that triblock copolymers containing click nucleic acids (CNAs) can be used to simultaneously load a prodrug enzyme (cytosine deaminase, CodA) and a chemotherapy drug (doxorubicin, DOX) in a single polymer nanoparticle. CNAs are synthetic analogs of DNA comprised of a thiolene backbone and nucleotide bases that can hybridize to complementary strands of DNA. In this study, CodA was appended with complementary DNA sequences and fluorescent dyes to allow its encapsulation in PEG-CNA-PLGA nanoparticles. The DNA-modified CodA was found to retain its enzyme activity for converting prodrug 5-fluorocytosine (5-FC) to active 5-fluorouracil (5-FU) using a modified fluorescent assay. The DNA-conjugated CodA was then loaded into the PEG-CNA-PLGA nanoparticles and tested for cell cytotoxicity in the presence of the 5-FC prodrug. To study the effect of coloading DOX and CodA within a single nanoparticle, cell toxicity assays were run to compare dually loaded nanoparticles with nanoparticles loaded only with either DOX or CodA. We show that the highest level of cell death occurred when both DOX and CodA were simultaneously entrapped and delivered to cells in the presence of 5-FC.

Full text of DOI:10.1021/acs.biomac.9b00040

Subscriber access provided by UNIV OF CAMBRIDGE
Article
Click Nucleic Acid Mediated Loading of Prodrug Activating Enzymes
in PEG-PLGA Nanoparticles for Combination Chemotherapy
Albert Harguindey, Shambojit Roy, Alexander W. Harris, Benjamin D.
Fairbanks, Andrew P. Goodwin, Christopher N. Bowman, and Jennifer N. Cha
Biomacromolecules, Just Accepted Manuscript • DOI: 10.1021/acs.biomac.9b00040 • Publication Date (Web): 18 Mar 2019
Downloaded from http://pubs.acs.org on March 18, 2019
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a service to the research community to expedite the dissemination
of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in
full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully
peer reviewed, but should not be considered the official version of record. They are citable by the
Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore,
the “Just Accepted” Web site may not include all articles that will be published in the journal. After
a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web
site and published as an ASAP article. Note that technical editing may introduce minor changes
to the manuscript text and/or graphics which could affect content, and all legal disclaimers and
ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or
consequences arising from the use of information contained in these “Just Accepted” manuscripts.
is published by the American Chemical Society. 1155 Sixteenth Street N.W.,
Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.

Page 1 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
Click Nucleic Acid Mediated Loading of Prodrug
Activating Enzymes in PEG-PLGA Nanoparticles
for Combination Chemotherapy
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Albert Harguindey,1 Shambojit Roy,1 Alexander W. Harris1, Benjamin D. Fairbanks,1
Andrew P. Goodwin,1,2 Christopher N. Bowman,1,2 Jennifer N. Cha1,2 *
1Department of Chemical and Biological Engineering and 2Materials Science and
Engineering Program, University of Colorado, Boulder
*To whom correspondence should be addressed: Jennifer.Cha@colorado.edu
KEYWORDS. Polymer, Click Nucleic Acids, Enzyme, Prodrug Activation
ABSTRACT The simultaneous delivery of multiple therapeutics to a single site has shown
promise for cancer targeting and treatment. However, because of the inherent differences
in charge and size between drugs and biomolecules, new approaches are required for co-
localization of unlike components in one delivery vehicle. In this work, we demonstrate
that triblock copolymers containing click nucleic acids (CNAs) can be used to
simultaneously load a prodrug enzyme (cytosine deaminase, CodA) and a chemotherapy
ACS Paragon Plus Environment
1

Biomacromolecules
Page 2 of 31
1
2
3
4
5
6
7
8
9
drug (doxorubicin, DOX) in a single polymer nanoparticle. CNAs are a synthetic analog of
DNA comprised of a thiolene backbone and nucleotide bases that can hybridize to
complementary strands of DNA. In this study, CodA was appended with complementary
DNA sequences and fluorescent dyes to allow its encapsulation in PEG-CNA-PLGA
nanoparticles. The DNA-modified CodA was found to retain its enzyme activity for
converting prodrug 5-fluorocytosine (5-FC) to active 5-fluorouracil (5-FU) using a
modified fluorescent assay. The DNA conjugated CodA was then loaded into the PEG-
CNA-PLGA nanoparticles and tested for cell cytotoxicity in the presence of the 5-FC
prodrug. To study the effect of co-loading DOX and CodA within a single nanoparticle,
cell toxicity assays were run to compare dually-loaded nanoparticles with nanoparticles
loaded only with either DOX or CodA. We show that the highest level of cell death
occurred when both DOX and CodA were simultaneously entrapped and delivered to cells
in the presence of 5-FC.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
INTRODUCTION
Nanotechnology-based approaches have led to large progress in delivering therapeutic
agents to cancerous sites in the body1 while reducing off-target side effects.1,2 To increase
efficacy, combination therapies have been proposed to eradicate tumors before they
develop problematic drug resistance.3–5 One such approach is to load multiple agents in
the same nanoparticle, including chemically-unlike moieties such as hydrophilic nucleic
acids or proteins and hydrophobic chemotherapy drugs such as doxorubicin or
ACS Paragon Plus Environment
2

Page 3 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
paclitaxel.3,6–9 This encapsulation approach is especially important for biomolecules that
require protection from proteolytic degradation the body’s immune system.10,11
Entrapping both hydrophobic and hydrophilic agents in a single carrier is difficult due to
their different solvent partition coefficients. While poly(lactic-co-glycolic acid) (PLGA)
particles produced using oil-in-water emulsions have been used, these often suffer in vivo
due to difficulties encountered in loading proteins, the overall long-term stability during
circulation as well as difficulties with producing them at diameters less than 200 nm.12
Because of this, proteins are more often conjugated with polymers such as polyethylene
glycol (PEG) or entrapped within a crosslinked or stimuli responsive nanoparticle.13
However, due to the inherently large differences in size and polarity between proteins and
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
hydrophobic drugs, and despite numerous advances in bioconjugation techniques14,15
,
co-entrapment within a single delivery vehicle has only been achieved through particle
formulations16–19 that rely on cationic polymers20,21 which can suffer due to rapid
elimination in vivo or show limited degree of success.22–31
In this work we show the use of synthetic nucleic acids-namely click nucleic acids or
CNAs-to enable the simultaneous entrapment and delivery of a prodrug enzyme, cytosine
deaminase (CodA), and the chemotherapy drug doxorubicin (DOX) in a single
nanoparticle by using a PEG-CNA-PLGA block polymer. Click nucleic acids (CNAs) are a
synthetic analog of DNA comprised of a thiolene backbone and nucleotide bases.32 We
have recently shown that CNA in the appropriate solvent environment can hybridize to
ACS Paragon Plus Environment
3

Biomacromolecules
Page 4 of 31
1
2
3
4
5
6
7
8
9
complementary strands of DNA.33 In addition, we recently demonstrated the successful
synthesis and production of PEG-CNA-PLGA nanoparticles and their utility for loading
both complementary strands of DNA along with pyrene as a preliminary study.34 In the
work shown here, we have advanced our previous findings by co-entrapping protein
therapeutics along with chemotherapy drugs in PEG-CNA-PLGA nanoparticles. To load
CodA into the PEG-CNA-PLGA nanoparticles, we first attached complementary DNA
sequences and dyes to the enzyme, work by Mirkin et al using DNA-modified proteins
showed the structural integrity and functionality was maintained after similar
conjugations.35 To ensure this continued to be true the DNA-modified CodA was tested
for enzymatic activity with the prodrug 5-fluorocytosine (5-FC) using a modified
fluorometric assay based on the o-phthaldehyde amino acid detection assay.36–38 The
DNA conjugated CodA was then loaded into the PEG-CNA-PLGA nanoparticles and tested
for cell cytotoxicity in the presence of 5-FC (Scheme 1). The effect of co-loading DOX and
CodA within a single nanoparticle was also studied and compared to using nanoparticles
loaded with either DOX or CodA alone showing that the highest level of cell death occurs
when both are simultaneously entrapped and delivered to cells in the presence of 5-FC
(Scheme 1).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Scheme 1. Graphic representation of PEG-CNA-PLGA nanoparticles co-loaded with
hydrophilic DNA-conjugated prodrug activating enzymes and hydrophobic
chemotherapy drugs.
ACS Paragon Plus Environment
4

Page 5 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
MATERIALS AND METHODS
Materials. AlexaFluor488 NHS ester (Invitrogen), DNA sequences (Integrated DNA
Tech.), ammonium chloride (Fisher), amphicillin (Sigma), biuret reagent (Sigma),
coomassie stain -simplyblue safestain- (Invitrogen), DBCO-NHS (Sigma), doxorubicin
(DOX, Tokyo chem. Indus.), Dulbecco's Modified Eagle Medium (Gibco), fetal bovine
serum (Gibco), fluorocytosine (5-FC, Sigma), fluorouracil (5-FU, Sigma), folin and coicalteu
phenol reagent (Sigma), gel cassettes -NuPage 4-12%- (Life Tech.), imidazole (Chem-
Impex int'l Inc.), isopropyl β-D-thiogalactopyranoside (IPTG, Gold Biotech.), L-glutamine-
penicillin-streptomycin solution (Sigma), loading buffer -LDS NuPage- (Invitrogen), MDA-
MB-468 cell line (ATCC), Ni-NTA Beads -HisPur- (Thermo), o-phtalaldehyde (Sigma),
poly(lactic-co-glycolic acid) -RG502H- (PLGA, Sigma), thiolated poly(ethyleneglycol) (PEG-
ACS Paragon Plus Environment
5

Biomacromolecules
Page 6 of 31
1
2
3
4
5
6
SH, Lysan Bio Inc.), trypsin-EDTA (GenDEPOT), tryptone (Becton Dickinson), yeast extract
(Becton Dickinson).
7
8
9
Cytosine deaminase (CodA) expression: E. Coli strain BL21(DE3) was used as the
template for amplifying CodA gene using the forward and reverse primer sequence given
below. The primers incorporate a HindIII site at the 5’ position and an XhoI site at the 3’
position of the amplified sequence. The amplification was done using a standard PCR
technique with a 65°C annealing temperature.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5’-3’: aagcttGGCGGTGGCTCGAATAACGCTTTACAAACAATTATTAAC
3’-5’: ctcgagACGTTTGTAATCGATGGCTTCT
Pet21B vector was digested for 1hr at 37°C with the mentioned restriction enzymes and
the primers treated using a standard ligation mixture supplied by NEB. Finally the ligated
plasmid was then transformed into the electrocompetent E. Coli DH5α using an Eppendorf
eporator at 1300 V. The transformed E. Coli was then incubated overnight on an agar plate
supplemented with Ampicillin as selection marker in order to create a 50% glycerol stock
solution stored at -21°C.
CodA production: CodA producing bacteria was pricked from the described glycerol
stock and incubated in 5ml of LB supplemented with 1mg/ml Ampicillin overnight at 37°C
in an orbital shaker. 1 ml of the activated bacteria was added to an Erlenmeyer flask
containing 100 ml of LB with the same antibiotic supplementation and allowed to grow
in the same incubation conditions until an absorbance of 0.7 at 600 nm was reached point
ACS Paragon Plus Environment
6

Page 7 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
at wich 100 µl of a 1M IPTG solution was added and allowed to express the protein in the
same incubation conditions for 2.5 h. The solutions were centrifuged 5 min at 10000 g,
the supernatant was discarded, and bacterial pellets were resuspended and collected in a
total of 25 ml Equilibration Buffer. The bacterial suspension was sonicated at 25% output
for 4 min in 1 min on/off cycles for 20 min and centrifuged at 12000 g and the supernatant
was collected for protein purification.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Protein purification: Ni-NTA beads were cleaned following company instructions. To
collect the CodA proteins, the bacterial supernatants were reacted with the cleaned Ni
beads and washed 2-3 times with wash buffer. Any absorbed proteins were released by
mixing the cleaned beads in 200µl of elution buffer for 30 min in an end to end shaker
and a last 2 min centrifugation at 700 g to obtain the purified CodA. Excess imidazole was
then removed with a desalting column, final product concentration was assessed by its
absorbance and stored at 4°C in PBS.
CodA DNA and dye modification: Varying concentrations of the purified CodA in PBS
was mixed with equal volume of Bicarbonate buffer to slightly increase the pH and reacted
in a 1:5 CodA to DBCO-NHS, to increase the solubility DMSO was added to the mixture
so that final DMSO concentration was of 30%. This was allowed to proceed 4 h at 4°C and
without further purification further reacted with 5 molar equivalents of NHS-
AlexaFluor488 at 4 °C overnight. This was followed by 20 kDa MWCO Dialysis; it was found
to be necessary to perform this step at 4°C to avoid protein degradation (data not
ACS Paragon Plus Environment
7

Biomacromolecules
Page 8 of 31
1
2
3
4
5
6
7
8
9
reported). Dialysis was performed against 1 L of PBS changed at 2, 4, 8, and then
approximately every 12 h. Samples of the dialysate were periodically taken in order to
monitor the process up to a total dialysis time of 72 h. The purified DBCO and dye
modified enzyme was then quantified by Ohnishi and Barr’s Lowry’s method -calibrated
with raw CodA quantified by its extinction coefficient (Figure S1)- and then mixed with
azido-DNA in a 1:5 ratio and left to react overnight at room temperature in an end to end
shaker protected from light. Final product was then again followed by a dialysis
purification and quantification as described previously.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
OPAME Assay: The developing solution was made by dissolving 270 mg (2 mmol) of o-
phthalaldehyde, 105 µl (1.5 mmol) of mercaptoethanol in 2.5 ml of ethanol and diluted to
50 ml with PBS. The solution was stored protected from light at room temperature and
an aliquot filtered through a 0.22 µm PTFE filter before use. When an assay was to be
performed equal volumes of the sample and the filtered developing reagent was mixed
in an Eppendorf tube and left reacting in the dark for 30 min before fluorometrically
assessing the concentration of an aliquot with 410 nm source excitation and a 473 nm
read. Calibration was performed by varying concentrations of NH4Cl finding a linear
response below 400 nM NH4Cl. The assay brightness was found to have a time response
(Figure S2) so it was deemed necessary to run the assay 30-60 min after adding the
reagent and for every run to include a calibration in parallel.
ACS Paragon Plus Environment
8

Page 9 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
Protein quantification: Protein was quantified by either an estimated 55550 cm-1 M-1
extinction coefficient39 at 380 nm or by an adapted Ohnishi and Barr modification of
Lowry’s method.40 Briefly, 110 µl of Biuret reagent was mixed with 10 µl of protein solution
and left reacting 10 min after which 5 µl of Folin and Coicalteu phenol reagent was added
and mixed thoroughly. 100 µl of the final solution was used for the spectrometric analysis
measuring the absorbance at 750 nm. Calibration was performed by using purified CodA
protein quantified by abs as described above so that the results reported are self-
consistent.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
PEG-CNA(T10)-PLGA Polymer Nanoparticles (NPs): The copolymer was synthesized as
previously reported and prior to use, anhydrously stored in a concentrated 50mg/ml DCM
solution at -21°C. Next, polymer NPs were formulated by dissolving PEG-CNA-PLGA in
methylene chloride (DCM) to a final concentration of 50 mg/ml. 100 µl of the polymer
solution was then added to a ½ dram glass vial containing 500 µl of PBS and 100 µl of
either clean DCM or a 250 µg/ml Doxorubicin (DOX) in DCM was further added according
to the type of NPs being made. After vigorous shaking, the solution was heated up to
37°C in an aluminum heating block and maintained uncapped for 2 h; the temperature
was then increased to 50°C and maintained 1 h to ensure evaporation of all remaining
DCM. While stirring the solution was left to equilibrate to room temperature (RT) before
centrifugation at 22000 g for 20 min. Supernatant was discarded and the nanoparticles
were resuspended in the appropriate volume of buffer for the next step. Particle sizes
ACS Paragon Plus Environment
9

Biomacromolecules
Page 10 of 31
1
2
3
4
5
6
were determined by nanoparticle tracking analysis, the results of which are shown in
Figure S3.
7
8
9
CodA entrapment in polymer nanoparticles: In a similar way to the previously reported
DNA conjugation,34 DNA conjugated 100 pmol of CodA was loaded per mg of
nanoparticles by mixing a 50 μl aliquot of the polymer nanoparticles, 20 μl of the modified
enzyme and 30 μl of DMSO. The reactions were left overnight at 4°C, diluted to 1 ml with
PBS and centrifuged for 20 min at 22000 g. After three washes, the final pellets were
resuspended in 100 μl of PBS. The amounts of encapsulated protein and DOX were
determined using calibration curves shown in Figures S4, S5 and S6.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Cell culture: MDA-MB-468 breast cancer cells were seeded at 37 °C in a 5% CO2
enriched atmosphere with Dulbecco's Modified Eagle Medium supplemented with 10%
(v/v) fetal bovine serum and 1% (v/v) penicillin-streptomycin. When cell density
approached confluence, the cells were incubated with 5 ml of trypsin for 5-15 min and
once detached centrifuged at 150 g for 5 min and resuspended in fresh media. Cell
concentration was estimated by a dual chamber hemocytometer. 0.5 to 1 million cells
were reseeded in a flask and 96 well plates were prepared by adding 100μl at 105 cells/ml
to each well needed for the assay. Cells were left overnight after seeding before any
further operation was performed.
Cell viability assay: To the cells seeded in a 96 well plate, 90 µL of either fresh media or
media supplemented with 5-FC was added. To that 10 µL of the appropriate concentration
ACS Paragon Plus Environment
10

Page 11 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
of nanoparticles to yield the desired final concentration was added followed by incubation
for 24 h at 37°C. Next, the cells were washed with PBS and replaced with 100 µL of new
media supplemented with MTT stock solution to contain 0.5 mg/ml of MTT. Results were
obtained by an absorbance reading at 560 nm and a reference reading at 650 nm.
Confocal imaging: Confocal microscopy slides were prepared analogously to the cell
viability assay by first seeding 1 ml of MDA-MB-468 at 5 x 104 cells/ml in a 24 well plate
pre-prepared to contain a glass slide. Cells where left to attach overnight followed by
incubation for 24 h then incubated 24 h with 1mg/ml of NPs. Right before the 24 h mark
10ml of cell media was warmed up to room temperature and 10 µl of a previously
prepared 0.2 mg/ml DAPI in DMSO (Stored at -21°C) was added together with 100 µl of
DiD 1mg/ml in DMSO. DAPI and DiD staining was used to image the cell nuclei and
membrane respectively. The staining media was discarded after 10 min of incubation with
the cells and washed twice more with PBS before immediately preparing the samples for
microscopy.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
RESULTS AND DISCUSSION
In this study, we first produced the prodrug enzyme cytosine deaminase (CodA) which
catalyzes the deamination of cytosine to uracil in microorganisms in the pyrimidine
synthetic pathway.41 For cancer therapy, CodA has been used to convert the prodrug
fluorocytosine (5-FC) to the active drug fluorouracil (5-FU), which is believed to inhibit
ACS Paragon Plus Environment
11

Biomacromolecules
Page 12 of 31
1
2
3
4
5
6
7
8
9
nucleotide synthetic enzyme thymidylate synthase.42 To produce CodA, we first expressed
the protein in BL21(DE3) (E. Coli) by inserting the gene in a Pet21B vector using HindIII
and Xhol as restriction enzymes followed by transfection through electroporation. Cells
were subsequently stored as a glycerol stock and then the enzyme was produced by
growing the cells in LB at 37°C and inducing with IPTG for 2.5 h when a 0.7 OD at 600 nm
was reached. Cells were lysed and CodA proteins were collected and purified using Ni-
NTA beads. The purity of the product was assessed by polyacrylamide gel electrophoresis
(SDS-PAGE) (Figure 1a) where a single band of ~50 kDa was observed.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The low toxicity of the prodrug 5-FC makes it an attractive therapy agent to target
cancer cells, provided that the enzyme can be site-specifically delivered.24 In order to load
CodA into our previously reported PLGA-CNA(T10)-PEG nanoparticles34 we first
conjugated the protein with polyadenine DNA strands so that the enzyme could
specifically bind to the polythymine CNA domain. In addition, to track protein loading
within the polymer nanoparticles, the enzyme was further modified with the dye
AlexaFluor488. To attach both DNA and dye to each protein, we reacted CodA first with
five molar equivalents of NHS-DBCO at pH 8.2 in 30% DMSO for 4 h. Next, NHS-
AlexaFluor488 was directly added to the protein reactions using a 1:5 protein:dye molar
ratio for 4 h. To prevent protein degradation all of the reactions were performed at 4°C.
Removing excess dye and NHS-DBCO from the proteins was done by dialysis at 4°C for
72 h. The products of each step were characterized by SDS-PAGE and as shown in Figure
ACS Paragon Plus Environment
12

Page 13 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
1a, specific bands that correspond to each modification step (dye attachment followed by
T10 or A10 conjugation) were detected. UV-Vis absorbance of the purified protein (Figure
1b) also confirms the successful conjugation of both the AlexaFluor488 dye and DNA
oligonucleotides and based on calibration curves (Figure S4) we were able to determine
~ 1 dye molecule and ~3-4 DNA strands were attached per protein. In addition, a gel run
with no Coomassie stain (Figure S7) showed the expected fluorescence from the
successful addition of the AlexaFluor488 dye.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 1. (a) SDS-PAGE gel of [1] protein ladder [2] unmodified CodA [3] CodA after DBCO
and AlexaFluor488 conjugation and after reacting with [4] A10 [5] T10 DNA. (b, c) UV-Vis
absorbance of the dye and DNA conjugated CodA.
Next, the dye and DNA conjugated CodA enzymes were tested for converting 5-FC to
5-FU to determine if modifying the protein either inhibited or hindered activity. For this,
while the traditional method is to detect a shift in the UV absorbance peak at 286 nm as
ACS Paragon Plus Environment
13

Biomacromolecules
Page 14 of 31
1
2
3
4
5
6
7
8
9
5-FC is converted to 5-FU,43 the strong absorbance at 260 nm of the DNA attached to the
enzyme (Figure 1b) obscured our ability to use UV-Vis to monitor activity. Therefore, a
common fluorescence technique that detects the presence of primary amines was
employed since ammonia is a byproduct of the 5-FC deamination to 5-FU (Figure 2a). O-
Phthalaldehyde becomes fluorescent only when reacted with both a sulfhydryl group and
a primary amine and thus can be used to assess the amount of 5-FC reacted with CodA
and spectrometrically quantify37 the progress of the reaction.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
To ascertain that the presence of 5-FC, CodA alone, or DNA and dye conjugated CodA
does not yield a fluorescent signal in the presence of o-phthalaldehyde and
mercaptoethanol (OPAME), we reacted 60 µl of each of the control substrates with 60 µl
of the OPAME solution (2 mmol o-phthalaldehyde, 1.5 mmol mercaptoethanol and 2.5 ml
EtOH) diluted to a final volume of 50 ml with PBS. Next, the reactions were incubated at
room temperature in the dark for 30 min followed by measuring fluorescence at 473 nm
(405 nm excitation). As shown in Figure 2b and Figure S2, little to no measurable
fluorescence could be detected indicating that the presence of amine groups on the
enzyme or prodrugs alone could not generate any fluorescence in the OPAME assay.
Next, 10 nM CodA (native, dye, DNA and dye conjugated) enzymes were reacted with
500 μM 5-FC and incubated in PBS at 37 °C while being continuously vigorously mixed in
an orbital shaker. At varying time points, aliquots were removed and assayed using the
OPAME test as described above. In order to determine the amount of ammonia being
ACS Paragon Plus Environment
14

Page 15 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
produced over time which should be in equimolar amounts to the amount of 5-FC
converted to 5-FU, calibration curves with NH4Cl were used (Figure S8) for each collected
time point. Because the intensity of the fluorescence response was found to decrease after
30-60 min, fluorescence measurements were run at a set point of 45 min after starting the
OPAME tests (Figure S2).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 2. (a) Scheme of the OPAME assay for determining 5-FC deamination rates (b)
Plots showing the amount of 5-FC converted to 5-FU over time as determined by the
ACS Paragon Plus Environment
15

Biomacromolecules
Page 16 of 31
1
2
3
4
5
6
7
8
9
OPAME assay. Samples were run with using 500 μM 5-FC or 5-FU in the absence of
presence of 10 nM CodA. All reactions were run in triplicate with each point showing the
average value obtained and subsequent error bars.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
As shown in Figure 2a, modifying the enzyme decreased the rate of 5-FC conversion,
regardless of whether the modification was with dye alone or DNA-dye. Because of the
nonspecific decrease in enzyme activity, we believe that the CodA activity is related in part
to the denaturation of the protein during the first reaction with NHS-DBCO as the
reactions were run at pH 8.2 and 30% DMSO which is also supported by the data shown
in Figure S9. Despite this decrease in activity, however, the enzyme is still capable of
activating a prodrug for cancer therapy.
Next, to encapsulate both CodA and a chemotherapy drug such as DOX in a single
carrier, the triblock copolymer PEG-CNA(T10)-PLGA was synthesized as reported in our
previous work.18 PEG-CNA(T10)-PLGA nanoparticles were then formulated by emulsifying
a solution of the polymer dissolved in methylene chloride with water and increasing the
temperature slowly under high stirring until all the organic solvent is evaporated, leaving
a nanoparticle mixture that could be collected and cleaned by high speed centrifugation.
Next, 200 pmol of the DNA and dye conjugated CodA proteins were reacted with 2 mg
of the PEG-CNA(T10)-PLGA nanoparticles at 30/70 DMSO/water overnight at 4°C followed
by 3 consecutive washes to remove any free, non-encapsulated protein. An aliquot was
lyophilized, weighed, and dissolved in pure DMSO to fluorometrically quantify the amount
ACS Paragon Plus Environment
16

Page 17 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
of CodA entrapped for a given mass of PEG-CNA(T10)-PLGA nanoparticles. As shown in
Figure 3a, using these methods we were able to discern that ~46 pmol (23%) of the added
DNA(A10)-CodA protein was encapsulated in ~ 2 mg of polymer nanoparticles. In
contrast, when the CodA protein was conjugated with either dye alone or T10 DNA, only
~12 pmol (6%) could be encapsulated, showing again that specific DNA-CNA
hybridization was needed to load the enzyme in the PEG-CNA-PLGA nanoparticles. In
addition to loading the CodA enzyme in the polymer nanoparticles, the chemotherapy
drug DOX could also be simultaneously entrapped by simply adding it in during the
polymer nanoparticle synthesis. Since the fluorescence emission of DOX (610 nm) is
separate from that of the AlexaFluor 488 dye on the enzyme, we were able to determine
~23 μg DOX could be loaded per mg of polymer nanoparticle (Figure 3b).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The CodA and DOX loaded polymer nanoparticles were next evaluated for cell killing
and compared to that of nanoparticles loaded with CodA or DOX alone. In this instance,
breast cancer MDA-MB-468 cell lines were used in an MTT assay, and all tests were done
in the presence of 5-FC. As controls, polymer nanoparticles were added with no DOX
loaded or no addition of 5-FC; 5-FU was also tested alone as a comparison. For all tests,
MDA-MB-468 cells were seeded and incubated overnight in 96 well plates at a cell density
of 104 cells per well. Next, the various therapy agents (polymer nanoparticles, CodA, DOX,
5-FC, 5-FU) were added and incubated with the cells for 24 h at 37°C. Next, the media was
removed, the cells were washed 2 times with PBS, and MTT assays were performed. As
ACS Paragon Plus Environment
17

Biomacromolecules
Page 18 of 31
1
2
3
4
5
6
7
8
9
shown in Figure 3c, compared to blank PLGA-CNA-PEG nanoparticles in the presence of
the prodrug 5-FC, the CodA loaded NPs show a significant increase in cell toxicity which
can be attributed to the enzyme activation of the prodrug. In comparing the CodA loaded
nanoparticles and 5-FC with 5-FU alone, highly comparable results in cell viability were
obtained demonstrating that although 5-FU can diffuse into cells immediately upon
adding to cells, the enzyme loaded polymer nanoparticles did not cause lower cell killing
capabilities as compared to the drug alone, despite the need for the prodrug 5-FC to
enter the polymer corona, diffuse to the enzyme embedded and react to produce the
active drug 5-FU. The polymer nanoparticles loaded with enzyme seemed to also show
higher cell killing as compared to enzyme alone with 5-FC, but this behavior may in part
be attributed to an inherent cell toxicity the PEG-CNA(T10)-PLGA nanoparticles seem to
show (‘Blank NPs + 5-FC’ as compared to the control of 5-FC alone) at the polymer
nanoparticle concentrations used (Figure S10). Lastly, the polymer nanoparticles loaded
with both CodA and DOX were tested with the MDA-MB-468 cells in the presence of the
prodrug 5-FC. As shown in Figure Figure 3c, comparing either DOX alone or DOX loaded
polymer nanoparticles, activating prodrugs in the vicinity of the cells along with DOX
delivery showed significant enhancement of cell killing, supporting the hypothesis that
delivering and activating multiple therapy agents using a single carrier can enhance
cancer cell eradication.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ACS Paragon Plus Environment
18

Page 19 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 3. (a) Estimated entrapment of DNA modified CodA for both a polyadenine and
polythymine modified enzyme. (b) Amount of Doxorubicin (c) MTT results of incubating
polymer nanoparticles with cells. All samples contained 500 μM of 5-FC except for the
first column (CodA) and the fourth one (5-FU). CodA and CodA+5FU samples contained
10 nM of the enzyme and 500 μM 5-FU. All nanoparticle samples contained ~1 mg/ml
NPs. The DOX alone test contained 23 µg/ml of the drug in solution -the estimated
amount encapsulated in the NPs. Blank and DOX NPs contained no enzyme. Error bars
represent the standard error calculated from a n=6, we estimated a *p<0.006 of the co-
loaded NPs being less toxic than Doxorubicin NPs, a **p < 0.031 for being more toxic than
CodA loaded NPs and a ***p < 10-7 of being less toxic than blank NPs for a normal
distribution.
ACS Paragon Plus Environment
19

Biomacromolecules
Page 20 of 31
1
2
3
4
5
6
7
8
9
Finally, confocal imaging was run to visually assess cellular uptake of the enzyme loaded
(no DOX) nanoparticles. For this, MDA-MB-468 cells were seeded in 24 well plates that
contained a glass slide in the bottom of each well. Cells were left to attach overnight
followed by incubating the cells with 1 mg/ml of the CodA loaded polymer nanoparticles
for 24 h. The slides where then washed with PBS and stained for 10 min at 37°C with
DMEM media containing 0.2 μg of DAPI and 10 μg of DiD per ml acting as a nuclear and
membrane stains respectively.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 4. Confocal imaging of MDA-MB-468 incubated for 24h with 1 mg/ml of
unconjugated NPs as well as particles reacted with AlexaFluor 488 modified cytosine
deaminase conjugated with either polyadenine or polythymine DNA. As shown, green
fluorescence from the AlexaFluor488 dye was only detected from cells incubated with
ACS Paragon Plus Environment
20

Page 21 of 31
Biomacromolecules
1
2
3
4
PEG-CNA(T10)-PLGA nanoparticles reacted with poly-A conjugated CodA, demonstrating
5
6
7
the specificity of CNA-DNA hybridization. Scale bars represent 50 μm.
8
9
As shown in Figure 4, only cells incubated with PEG-CNA(T10)-PLGA nanoparticles
loaded with DNA(A10)-AlexaFluor488 conjugated CodA showed any marked fluorescence
in the green, showing not only that CodA is indeed entrapped in the polymer
nanoparticles but also that the enzyme is being delivered intracellularly. Cells incubated
with polymer nanoparticles reacted with DNA(T10)-AlexaFluor488 conjugated CodA
showed nearly zero green emission supporting the earlier results that enzyme loading in
the PEG-CNA(T10)-PLGA nanoparticles is dependent on specific CNA-DNA hybridization.
Lastly, cell uptake kinetic analyses were performed by reacting seeded MDA-MB-468 cells
with DOX loaded PEG-CNA(T10)-PLGA nanoparticles and at various time points, removing
the media and measuring intracellular delivery of the nanoparticles by flow cytometry. As
shown in Figure S11, nanoparticle uptake appeared to reach a maximum value after ~ 5
h incubation with cells with little to no change up to 10 h of measurement.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONCLUSION
In this work we have shown the successful simultaneous entrapment of the prodrug
activating enzyme cytosine deaminase (CodA) with the chemotherapy drug doxorubicin (DOX)
within a single polymer nanoparticle. This result was achieved by conjugating the protein with
polyadenine strands, then using complementary base pairing to PEG-CNA(T10)-PLGA to
ACS Paragon Plus Environment
21

Biomacromolecules
Page 22 of 31
1
2
3
4
5
6
7
8
9
incorporate the enzyme into preformed polymer nanoparticles that could also be loaded with DOX.
To test for prodrug activation by the DNA conjugated CodA, a fluorometric assay based on o-
phthalaldehyde was developed, which showed that despite some nonspecific decrease in activity,
the DNA-modified CodA retained the ability to convert prodrug 5-FC to active drug 5-FU. After
encapsulating the DNA-CodA in PEG-CNA-PLGA nanoparticles, cell toxicity assays were
performed against MDA-MB-468 breast cancer cells. These results showed low toxicity with
particles alone in the presence of 5-FC but a significant increase in cell killing upon loading with
DNA-CodA. Furthermore, the toxic effects were compounded when the hydrophobic drug
doxorubicin was also encapsulated, showing potential for adapting this technique in the co-
delivery of chemotherapy agents. Lastly, confocal imaging was used to demonstrate successful
targeting of the cells with the enzyme loaded PEG-CNA-PLGA nanoparticles, and that
complementary base pairing was required to associate the CNA strands of the polymer with the
DNA oligonucleotides on the enzyme.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ASSOCIATED CONTENT
This present work is accompanied by the submission of supplementary information
including a fluorescently scanned SDS-PAGE gel showing dye conjugation on the studied
proteins (Figure S7), calibration lines used in protein quantification in the studied solvents
in all the mentioned methods described in the main text (S1, S4, S5 and S6), the resulting
calibration for the developed OPAME assay (S8) as well as its time stability (S2), a brief
study on the inherent toxicity of the described blank NPs (S10), an assay on denaturing
effects of the reaction conditions on codA (S9), NTA of the studied NPs (S3) and finally a
cytometry test on the delivered DOX on cells with the studied NPs (S11).
ACS Paragon Plus Environment
22

Page 23 of 31
Biomacromolecules
1
2
3
4
5
6
7
AUTHOR INFORMATION
8
9
Corresponding Author
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
*To whom correspondence should be addressed: Jennifer.Cha@colorado.edu
Funding Sources
We gratefully acknowledge financial support from NSF-MRSEC (DMR1420736) and the
National Institutes of Health Award # DP2EB020401
ACKNOWLEDGMENT
A.H. gratefully acknowledges the initial support of the Balsells fellowship program.
REFERENCES
(1)
(2)
(3)
Miller, K. D.; Siegel, R. L.; Lin, C. C.; Mariotto, A. B.; Kramer, J. L.; Rowland, J. H.; Stein,
K. D.; Alteri, R.; Jemal, A. Cancer Treatment and Survivorship Statistics, 2016. CA.
Cancer J. Clin. 2016, 66 (4), 271–289. https://doi.org/10.3322/caac.21349.
Krishnan, V.; Rajasekaran, A. K. Clinical Nanomedicine: A Solution to the
Chemotherapy Conundrum in Pediatric Leukemia Therapy. Clin. Pharmacol. Ther.
2014, 95 (2), 168–178. https://doi.org/10.1038/clpt.2013.174.
Kemp, J. A.; Shim, M. S.; Heo, C. Y.; Kwon, Y. J. “Combo” Nanomedicine: Co-Delivery
ACS Paragon Plus Environment
23

Biomacromolecules
Page 24 of 31
1
2
3
4
5
6
of Multi-Modal Therapeutics for Efficient, Targeted, and Safe Cancer Therapy. Adv.
Drug Deliv. Rev. 2016, 98, 3–18. https://doi.org/10.1016/j.addr.2015.10.019.
7
8
9
(4)
Morton, S. W.; Lee, M. J.; Deng, Z. J.; Dreaden, E. C.; Siouve, E.; Shopsowitz, K. E.;
Shah, N. J.; Yaffe, M. B.; Hammond, P. T. A Nanoparticle-Based Combination
Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Signaling
Pathways.
Sci.
Signal.
2014,
7
(325).
https://doi.org/10.1126/scisignal.2005261.
(5)
(6)
(7)
Burrell, R. A.; McGranahan, N.; Bartek, J.; Swanton, C. The Causes and Consequences
of Genetic Heterogeneity in Cancer Evolution. Nature 2013, 501 (7467), 338–345.
https://doi.org/10.1038/nature12625.
Li, H.; Chen, L.; Shi, Y.; Yuan, B.; Ma, Y.; Wei, H.; Zhao, G. Design of Block Copolymer
Micellar Aggregates for Co-Delivery of Enzyme and Anticancer Prodrug. Chem. - An
Asian J. 2017, 12 (2), 176–180. https://doi.org/10.1002/asia.201601198.
Chen, L.; Liu, Z.; Jin, R.; Yang, X.; Bai, Y.; Liu, S.; Chen, X. Stepwise Co-Delivery of an
Enzyme and Prodrug Based on a Multi-Responsive Nanoplatform for Accurate
Tumor Therapy. J. Mater. Chem.
B
2018,
6
(39), 6262–6268.
https://doi.org/10.1039/C8TB01182F.
(8)
Zheng, C.; Zheng, M.; Gong, P.; Deng, J.; Yi, H.; Zhang, P.; Zhang, Y.; Liu, P.; Ma, Y.;
Cai, L. Polypeptide Cationic Micelles Mediated Co-Delivery of Docetaxel and SiRNA
ACS Paragon Plus Environment
24

Page 25 of 31
Biomacromolecules
1
2
3
4
for Synergistic Tumor Therapy. Biomaterials 2013, 34 (13), 3431–3438.
5
6
7
https://doi.org/10.1016/j.biomaterials.2013.01.053.
8
9
(9)
Qu, M. H.; Zeng, R. F.; Fang, S.; Dai, Q. S.; Li, H. P.; Long, J. T. Liposome-Based Co-
Delivery of SiRNA and Docetaxel for the Synergistic Treatment of Lung Cancer. Int.
J. Pharm. 2014, 474 (1–2), 112–122. https://doi.org/10.1016/j.ijpharm.2014.08.019.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(10) Zhang, Y.; Satterlee, A.; Huang, L. In Vivo Gene Delivery by Nonviral Vectors:
Overcoming Hurdles? Mol. Ther. 2012, 20 (7), 1298–1304.
https://doi.org/10.1038/mt.2012.79.
(11) Milton Harris, J.; Chess, R. B. Effect of Pegylation on Pharmaceuticals. Nat. Rev. Drug
Discov. 2003, 2 (3), 214–221. https://doi.org/10.1038/nrd1033.
(12) Hanson, J. A.; Chang, C. B.; Graves, S. M.; Li, Z.; Mason, T. G.; Deming, T. J. Nanoscale
Double Emulsions Stabilized by Single-Component Block Copolypeptides. Nature
2008, 455 (7209), 85–88. https://doi.org/10.1038/nature07197.
(13) Tseng, Y. C.; Mozumdar, S.; Huang, L. Lipid-Based Systemic Delivery of SiRNA. Adv.
Drug Deliv. Rev. 2009, 61 (9), 721–731. https://doi.org/10.1016/j.addr.2009.03.003.
(14) Soppimath, K. S.; Aminabhavi, T. M.; Kulkarni, A. R.; Rudzinski, W. E. Biodegradable
Polymeric Nanoparticles as Drug Delivery Devices. J. Control. Release 2001, 70 (1–
2), 1–20. https://doi.org/10.1016/S0168-3659(00)00339-4.
ACS Paragon Plus Environment
25

Biomacromolecules
Page 26 of 31
1
2
3
4
(15) Mahon, E.; Salvati, A.; Baldelli Bombelli, F.; Lynch, I.; Dawson, K. A. Designing the
5
6
7
Nanoparticle–biomolecule Interface for “Targeting and Therapeutic Delivery.” J.
8
9
Control.
Release
2012,
161
(2),
164–174.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
https://doi.org/10.1016/j.jconrel.2012.04.009.
(16) Saad, M.; Garbuzenko, O. B.; Minko, T. Co-Delivery of SiRNA and an Anticancer Drug
for Treatment of Multidrug-Resistant Cancer. Nanomedicine 2008, 3 (6), 761–776.
https://doi.org/10.2217/17435889.3.6.761.
(17) Lee, A. L. Z.; Wang, Y.; Cheng, H. Y.; Pervaiz, S.; Yang, Y. Y. The Co-Delivery of
Paclitaxel and Herceptin Using Cationic Micellar Nanoparticles. Biomaterials 2009,
30 (5), 919–927. https://doi.org/10.1016/j.biomaterials.2008.10.062.
(18) Huang, Y.; Yu, F.; Park, Y.-S.; Wang, J.; Shin, M.-C.; Chung, H. S.; Yang, V. C. Co-
Administration of Protein Drugs with Gold Nanoparticles to Enable Percutaneous
Delivery.
Biomaterials
2010,
31
(34),
9086–9091.
https://doi.org/10.1016/j.biomaterials.2010.08.046.
(19) Jiang, T.; Mo, R.; Bellotti, A.; Zhou, J.; Gu, Z. Gel-Liposome-Mediated Co-Delivery of
Anticancer Membrane-Associated Proteins and Small-Molecule Drugs for Enhanced
Therapeutic Efficacy. Adv. Funct. Mater. 2014, 24 (16), 2295–2304.
https://doi.org/10.1002/adfm.201303222.
(20) Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. Toxicity of Cationic Lipids and Cationic
ACS Paragon Plus Environment
26

Page 27 of 31
Biomacromolecules
1
2
3
4
Polymers in Gene Delivery. J. Control. Release 2006, 114 (1), 100–109.
5
6
7
https://doi.org/10.1016/j.jconrel.2006.04.014.
8
9
(21) Choi, C. H. J.; Hao, L.; Narayan, S. P.; Auyeung, E.; Mirkin, C. A. Mechanism for the
Endocytosis of Spherical Nucleic Acid Nanoparticle Conjugates. Proc. Natl. Acad. Sci.
2013, 110 (19), 7625–7630. https://doi.org/10.1073/pnas.1305804110.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(22) Gaumet, M.; Vargas, A.; Gurny, R.; Delie, F. Nanoparticles for Drug Delivery: The
Need for Precision in Reporting Particle Size Parameters. Eur. J. Pharm. Biopharm.
2008, 69 (1), 1–9. https://doi.org/10.1016/j.ejpb.2007.08.001.
(23) Champion, J. A.; Katare, Y. K.; Mitragotri, S. Particle Shape: A New Design Parameter
for Micro- and Nanoscale Drug Delivery Carriers. J. Control. Release 2007, 121 (1–
2), 3–9. https://doi.org/10.1016/j.jconrel.2007.03.022.
(24) Kulkarni, S. A.; Feng, S. Effects of Particle Size and Surface Modification on Cellular
Uptake and Biodistribution of Polymeric Nanoparticles for Drug Delivery. Pharm.
Res. 2013, 30 (10), 2512–2522. https://doi.org/10.1007/s11095-012-0958-3.
(25) Bazile, D. V.; Ropert, C.; Huve, P.; Verrecchia, T.; Mariard, M.; Frydman, A.; Veillard,
M.; Spenlehauer, G. Body Distribution of Fully Biodegradable [14C]-Poly(Lactic Acid)
Nanoparticles Coated with Albumin after Parenteral Administration to Rats.
Biomaterials 1992, 13 (15), 1093–1102. https://doi.org/10.1016/0142-
9612(92)90142-B.
ACS Paragon Plus Environment
27

Biomacromolecules
Page 28 of 31
1
2
3
4
5
6
7
8
9
(26) Cheng, J.; Teply, B. a.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.;
Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of Functionalized
PLGA-PEG Nanoparticles for in Vivo Targeted Drug Delivery. Biomaterials 2007, 28
(5), 869–876. https://doi.org/10.1016/j.biomaterials.2006.09.047.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(27) Danhier, F.; Ansorena, E.; Silva, J. M.; Coco, R.; Le Breton, A.; Préat, V. PLGA-Based
Nanoparticles: An Overview of Biomedical Applications. J. Control. Release 2012,
161 (2), 505–522. https://doi.org/10.1016/j.jconrel.2012.01.043.
(28) Dziubla, T. D.; Karim, A.; Muzykantov, V. R. Polymer Nanocarriers Protecting Active
Enzyme Cargo against Proteolysis. J. Control. Release 2005, 102 (2), 427–439.
https://doi.org/10.1016/j.jconrel.2004.10.017.
(29) Hosseininasab, S.; Pashaei-Asl, R.; Khandaghi, A. A.; Nasrabadi, H. T.; Nejati-Koshki,
K.; Akbarzadeh, A.; Joo, S. W.; Hanifehpour, Y.; Davaran, S. Synthesis,
Characterization, and in Vitro Studies of PLGA-PEG Nanoparticles for Oral Insulin
Delivery.
Chem.
Biol.
Drug
Des.
2014,
84
(3),
307–315.
https://doi.org/10.1111/cbdd.12318.
(30) Crotts, G.; Park, T. G. Protein Delivery from Poly(Lactic-Co-Glycolic Acid)
Biodegradable Microspheres: Release Kinetics and Stability Issues. J. Microencapsul.
1998, 15 (6), 699–713. https://doi.org/10.3109/02652049809008253.
(31) Zheng, C.-H.; Gao, J.-Q.; Zhang, Y.-P.; Liang, W.-Q. A Protein Delivery System:
ACS Paragon Plus Environment
28

Page 29 of 31
Biomacromolecules
1
2
3
4
5
6
7
8
9
Biodegradable Alginate–chitosan–poly(Lactic-Co-Glycolic Acid) Composite
Microspheres. Biochem. Biophys. Res. Commun. 2004, 323 (4), 1321–1327.
https://doi.org/10.1016/j.bbrc.2004.09.007.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(32) Xi, W.; Pattanayak, S.; Wang, C.; Fairbanks, B.; Gong, T.; Wagner, J.; Kloxin, C. J.;
Bowman, C. N. Clickable Nucleic Acids: Sequence-Controlled Periodic
Copolymer/Oligomer Synthesis by Orthogonal Thiol-X Reactions. Angew. Chemie
Int. Ed. 2015, 54 (48), 14462–14467. https://doi.org/10.1002/anie.201506711.
(33) Han, X.; Domaille, D. W.; Fairbanks, B. D.; He, L.; Culver, H. R.; Zhang, X.; Cha, J. N.;
Bowman, C. N. New Generation of Clickable Nucleic Acids: Synthesis and Active
Hybridization
with
DNA.
Biomacromolecules
2018,
19,
4139–4146.
https://doi.org/10.1021/acs.biomac.8b01164.
(34) Harguindey, A.; Domaille, D. W.; Fairbanks, B. D.; Wagner, J.; Bowman, C. N.; Cha, J.
N. Synthesis and Assembly of Click-Nucleic-Acid-Containing PEG-PLGA
Nanoparticles for DNA Delivery. Adv. Mater. 2017, 29 (24), 1700743.
https://doi.org/10.1002/adma.201700743.
(35) Brodin, J. D.; Sprangers, A. J.; McMillan, J. R.; Mirkin, C. A. DNA-Mediated Cellular
Delivery of Functional Enzymes. J. Am. Chem. Soc. 2015, 137 (47), 14838–14841.
https://doi.org/10.1021/jacs.5b09711.
(36) Roth, M. Fluorescence Reaction for Amino Acids. Anal. Chem. 1971, 43 (7), 880–882.
ACS Paragon Plus Environment
29